BridgeBio Pharma, Inc. (BBIO) News

BridgeBio Pharma, Inc. (BBIO): $50.16

-0.02 (-0.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter BBIO News Items

BBIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BBIO News Highlights

  • BBIO's 30 day story count now stands at 7.
  • Over the past 23 days, the trend for BBIO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about BBIO are ALTO and GENE.

Latest BBIO News From Around the Web

Below are the latest news stories about BridgeBio Pharma Inc that investors may wish to consider to help them evaluate BBIO as an investment opportunity.

BridgeBio Pharma's Candidate For Muscle-Wasting Disorder Wins Fast Track Tag In US

The FDA has granted Fast Track Designation to BridgeBio Pharma Inc's (NASDAQ: BBIO) BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i). This is the fifth Fast Track designation for an investigational therapy that BridgeBio has received this year. Clinical trials to verify the safety and efficacy of BBP-418 are ongoing. BBP-418 has received Orphan Drug Designation for the treatment of LGMD2i from the FDA and LGMD from the European Medicines Agency. LGMD2i is a monog

Yahoo | September 15, 2021

BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that the United States Food and Drug Administration (FDA) granted Fast Track designation for the investigation of BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i). The FDA grants development programs Fast Track designation to

Yahoo | September 15, 2021

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that on September 2, 2021, the compensation committee of BridgeBio's board of directors granted 29 new employees restricted stock units for an aggregate of 61,210 shares of the Company's common stock. All of the above-described awards were made under BridgeB

Yahoo | September 8, 2021

Should You Be Tempted To Sell BridgeBio Pharma (BBIO) Stock?

No summary available.

Insider Monkey | August 30, 2021

Should You Be Tempted To ‘Sell’ BridgeBio Pharma (BBIO) Stock?

Baron Opportunity Fund recently published its second-quarter commentary – a copy of which can be downloaded here. During the second quarter of 2021, the Baron Opportunity Fund returned 10.14% (institutional shares). In comparison, the benchmark S&P 500 Index was up 8.55%, while the Russell 3000 Growth Index was up 11.38%. You should check out Baron’s […]

Yahoo | August 30, 2021

BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors

PALO ALTO, Calif. & SHANGHAI & PRINCETON, N.J., August 25, 2021--LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced the first patient has been treated in a Phase 2a clinical trial of infigratinib in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with fibroblast growth factor receptor-2 (FGFR2) gene a

Yahoo | August 25, 2021

10 Best Stocks to Invest In According to Chinese Billionaire Lei Zhang

In this article, we will discuss 10 best stocks to invest in according to Chinese billionaire Lei Zhang based on Q1 holdings of the fund. If you want to skip our detailed analysis of Zhang’s history, investment philosophy, and hedge fund performance, go directly to 5 Best Stocks to Invest In According to Chinese Billionaire Lei […]

Yahoo | August 23, 2021

BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors

PALO ALTO, Calif., Aug. 18, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today…

PR Newswire | August 18, 2021

Baron Funds: “We Retain Conviction in BridgeBio (BBIO)”

Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. A return of 11.43% was delivered by the fund’s institutional shares for the Q2 of 2021, outperforming both its S&P 500 and Russell 3000 Health Care benchmarks that delivered […]

Yahoo | August 18, 2021

New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) shareholders will have a reason to smile today, with the analysts making...

Yahoo | August 7, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6236 seconds.